Rectivard is considered relevant for easing symptoms related to physical discomfort and conditions characterized by periods of heightened symptoms. It is applied across therapeutic domains where additional symptomatic support is needed.

Rectivard is commonly used across domains involving significant symptomatic burden, representing a standard therapeutic approach. The medication is commonly used to help with symptoms such as general body aches, headache, joint stiffness, and fever.

“Rectivard provides supportive relief when symptoms interfere with routine activities, and contributes to improved day-to-day comfort during symptomatic periods.”

Symptom Clusters Managed

This medication is generally used to help manage symptom clusters that may become intense or disruptive, such as those related to inflammatory or irritative states and acute, episodic symptom escalation. It is relevant for conditions presenting with systemic or localized discomfort and is often applied during phases when symptoms become more noticeable. Rectivard provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability.

Quick Fact: Relevant for Pain, Fever, and Inflammation

Regulatory References

1. NIH MedlinePlus overview on NSAIDs

Rectivard (Vardenafil) is officially indicated for use only in adult men (ge18 years of age). Eligibility is subject to strict exclusions based on concurrent medications and underlying medical status, as defined by regulatory agencies.

Contraindicated Populations (Must Not Use)

Classification	Population Group/Condition
Absolute Ban	Use of nitrate medications or Guanylate Cyclase (sGC) stimulators (e.g., riociguat).
Organ Function	Patients with severe hepatic impairment (Child-Pugh C) or end-stage renal disease (dialysis).
Medical History	Individuals with a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

Restricted or Conditional Use

Use is not recommended or requires caution in patients for whom sexual activity is medically inadvisable due to certain cardiovascular conditions (e.g., recent stroke or myocardial infarction, unstable angina). Special consideration is required for older adults (ge65 years) and patients with moderate hepatic impairment or pre-existing conditions that predispose to a prolonged erection, such as sickle cell anaemia or Peyronie's disease.

Age and Gender Status

The medicine is not indicated for use in women (including during pregnancy or lactation) or in the pediatric population; safety and effectiveness have not been established in these groups.

The interaction profile for Rectivard is defined by its metabolic clearance and vascular effects, resulting in several formal prohibitions and constraints documented by regulatory authorities.

Formal Prohibitions and Contraindications

Co-administration is strictly contraindicated with any form of Organic Nitrates or Nitric Oxide Donors due to the documented risk of severe, potentially life-threatening hypotension. This prohibition also extends to Guanylate Cyclase Stimulators (e.g., Riociguat). Strong inhibitors of the CYP3A4 enzyme, such as the HIV protease inhibitors Ritonavir and Indinavir, must not be co-administered due to dangerously high increases in Vardenafil exposure. The combination with oral forms of Ketoconazole or Itraconazole is also contraindicated in men aged 75 years and older.

Pharmacokinetic and Pharmacodynamic Interactions

Rectivard is primarily cleared via the hepatic CYP3A4 enzyme. Inhibition of this enzyme leads to increased systemic levels; for instance, moderate inhibitors like Erythromycin are documented to increase Vardenafil exposure significantly. Rectivard may potentiate the hypotensive effects of Alpha-Blockers (e.g., Terazosin, Tamsulosin), which necessitates a low initial starting dose when co-therapy is initiated in stable patients. Grapefruit Juice is expected to increase Vardenafil plasma concentrations, and regulatory documentation states that this substance should be avoided. Increased exposure risk is also documented for patient populations with Moderate Hepatic Impairment and Severe Renal Impairment.

Rectivard: Mechanism of Action

Rectivard functions as a highly selective inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which is predominantly expressed in vascular smooth muscle. The drug acts by binding to and blocking the active site of PDE5, thereby preventing the enzyme's natural role: the hydrolysis (breakdown) of cyclic Guanosine Monophosphate (cGMP). This inhibition sustains elevated intracellular concentrations of cGMP.

Elevated cGMP levels within the smooth muscle cells prolong the signal for muscle relaxation and subsequent vasodilation (arterial widening). This action is dependent upon the prior physiological release of nitric oxide (NO), meaning Rectivard potentiates the existing signal rather than initiating a new one. The final physiological consequence of this targeted vasodilation is increased localized arterial inflow and corresponding increased turgidity of the vascularized tissue.

How Rectivard is Used: Official Administration Guidelines

The official administration guidelines for Rectivard, which contains Vardenafil, establish a specific, non-scheduled protocol for its oral use. For most adult patients, the standard starting dose is 10 mg, taken approximately 60 minutes before sexual activity. The dose may subsequently be adjusted to a minimum of 5 mg or a maximum of 20 mg based on the documented individual response. The maximum dosing frequency is once per day.

The medicine is available as both Film-Coated Tablets (FCT) and an Orally Disintegrating Tablet (ODT). While the FCT may be taken with or without food, the ODT must be placed directly on the tongue to disintegrate and is taken without liquid. A critical procedural constraint is that the 10 mg ODT formulation is not interchangeable with the 10 mg FCT, as the former provides a different systemic exposure.

Usage is also determined by specific patient characteristics. For older adults (age ≥ 65 years), a starting dose of 5 mg should be considered. Similarly, patients with moderate hepatic impairment (Child-Pugh B) are recommended to start with 5 mg, and their maximum dose is restricted to 10 mg. Crucially, the medicine is used on an as-needed basis and requires sexual stimulation to achieve its intended effect. The intermittent nature of the use means a fixed-schedule missed-dose protocol is not applicable.

Rectivard: Recent Clinical Evidence

Evidence for use in Erectile Dysfunction (ED)

This section summarizes the structure of the primary clinical research that investigated Rectivard's use for this condition, focusing on the types of controlled trials and validated measures that were deployed to evaluate functional outcomes.

Scientific research explored Rectivard in research exploring Erectile Dysfunction (ED) primarily through short- to intermediate-term Randomized Controlled Trials (RCTs). These studies were designed to be double-blind and placebo-controlled. Research examined outcomes related to functional imbalance specifically using measures from the International Index of Erectile Function (IIEF) and patient-reported outcomes describing perceived discomfort.

The main focus of these trials was monitoring patient-reported outcomes describing perceived discomfort and measures of functioning. Key functional measures included patient self-assessment of the ability to achieve and maintain erection. Studies reported how symptoms evolved in the observed populations, and data show patterns related to measured outcomes between the groups receiving Rectivard and the groups receiving placebo.

Long-Term Research and Durability of Response

The core research was conducted over defined time intervals, with many pivotal clinical evaluation studies limited to a duration of approximately 12 weeks. While some post-approval research and open-label extension studies were conducted for periods up to six months or, in limited populations, longer, long-term effects are not fully established based on the initial controlled trials. The evidence contributes to the broader evidence landscape, but there is limited information for long-term outcomes.

Evidence in Special Adult Populations

Rectivard was evaluated in specific patient subgroups whose conditions are characterized by functional limitations. This includes men with co-existing diagnoses like Type 1 or Type 2 Diabetes Mellitus and hypertension. These studies contribute to the broader evidence landscape for how these specific groups of patients reported their experience during the study period.

The Strength of the Evidence and Research Gaps

The overall evidence base, largely consisting of well-designed RCTs, was observed to have a high degree of consistency, and is designated as High by scientific reviews. Follow-up durations were limited in the primary controlled trials, and research exploring direct head-to-head assessments against other treatments is limited. Additionally, findings were mixed when analyzed across men with different underlying causes of ED, and data for certain groups remain insufficient. Research is ongoing to further explore these areas.

Common questions about Rectivard (FAQ)

Q: Is Rectivard a long-term or short-term medication?

A: Rectivard is described in official documents as being for 'use as needed' before sexual activity, and it is not intended for continuous daily use. While the medicine is used intermittently, primary clinical studies were generally conducted over short to intermediate-term intervals, such as up to 12 weeks.

Q: Does Rectivard affect sleep or cause drowsiness?

A: Official safety documents list somnolence (sleepiness) and sleep disorder as possible reported adverse reactions. Additionally, common effects like dizziness and visual disturbances are also reported, which could potentially impact rest or alertness.

Q: Does Rectivard interact with supplements like vitamins or herbal remedies?

A: Regulatory documents state that it is important to share information with a healthcare provider about any prescription or over-the-counter medicines, vitamins/minerals, herbal products, and other supplements being used. Specifically, Grapefruit products are expected to increase the amount of Rectivard in the body.

Q: What happens if a dose of Rectivard is missed?

A: Rectivard is used only as needed before sexual activity, not on a fixed daily schedule. Because of this, there is no protocol or instruction for a 'missed dose' as would be the case with medicines that must be taken every day.

Q: How quickly does Rectivard start to work after taking it?

A: The medicine is generally recommended to be taken approximately 25 to 60 minutes before sexual activity.

Q: Do studies show Rectivard is effective for all patients?

A: Clinical trial data indicate that Rectivard was observed to be more effective than placebo for its approved use. However, research documents also note that the findings were mixed when outcomes were analyzed across men with different underlying causes of the condition being addressed.

Q: Is it common to feel [Vague, non-clinical symptom like 'a bit off'] when starting Rectivard?

A: The most frequently reported effects in clinical trials are headache and flushing. Other commonly reported physical changes include dizziness, dyspepsia (indigestion), and nasal congestion. These are the most common physical changes reported by patients when starting the medicine.

Q: Does Rectivard need to be taken with food?

A: The film-coated tablets may be taken with or without food, although consuming them with a high-fat meal may result in a delay in the onset of the medicine's activity. The orally disintegrating tablets (ODT) must be placed directly on the tongue to dissolve and are taken without liquid or food.

Q: Is Rectivard known to interact with alcohol?

A: Regulatory sources advise that Rectivard can lower blood pressure, and combining it with alcohol may further increase this effect. This combination may be associated with symptoms such as dizziness, lightheadedness, and headache.

Q: What is the risk of dependence or addiction with Rectivard?

A: The potential for dependence or addiction is not described as a formal risk in the official prescribing information.

Q: What percentage of people report experiencing side effects on Rectivard?

A: Official safety data shows that the most frequent side effect, headache, is reported as 'Very Common,' meaning it occurs in more than 1 in 10 individuals. Other 'Common' adverse reactions (such as flushing and dizziness) are reported in 1 to 10 in 100 individuals.

Q: Can Rectivard affect my driving or ability to concentrate?

A: Because the medicine may cause dizziness or visual disturbances, patients are advised to be aware of how they respond to Rectivard. Patients are advised to be aware of how they respond to Rectivard before engaging in activities like driving or operating machinery.

Q: Are the side effects of Rectivard permanent?

A: Most common adverse reactions are generally transient. However, rare but very serious adverse reactions, such as Priapism (a prolonged erection) or sudden loss of vision, are associated with a risk of long-term or permanent injury if not addressed promptly.

Q: Is there a generic version of Rectivard available?

A: Yes. Following the expiry of certain patents, an approved generic version containing the active ingredient Vardenafil is commercially available.

Q: How long does Rectivard stay in your system?

A: The active substance, Vardenafil, has a relatively short elimination half-life of approximately 4 hours. This measure indicates the time it takes for half of the substance to be eliminated from the body's plasma.

Q: Are there any specific foods that interact with Rectivard?

A: While the film-coated tablets can be taken with or without a non-high-fat meal, regulatory documents specifically advise that Grapefruit Juice is expected to increase the level of the medicine in the body.

Q: Can the effectiveness of Rectivard decrease over time?

A: The primary pivotal clinical studies were conducted over a short duration, typically 12 weeks. While long-term data is limited from these initial trials, there are no formal regulatory statements that describe a reduction in effectiveness over time based on the available evidence.

Q: Do the official safety classifications of Rectivard restrict its use in certain populations?

A: Yes. Official safety classifications, called Contraindications, strictly prohibit the use of Rectivard in patients taking any form of nitrate medicine or Guanylate Cyclase stimulators. Use is also restricted for individuals with severe liver impairment or a history of specific vision loss (NAION).

Q: Why are there different strengths or formulations of Rectivard?

A: The medicine is available in multiple strengths to allow for dose adjustment based on the documented individual response and tolerability, as well as specific patient characteristics (such as age or level of kidney/liver impairment). The Orally Disintegrating Tablet (ODT) formulation provides an alternative route of administration for patient preference.

Q: Is Rectivard used for any condition other than its main approved uses?

A: Rectivard is formally indicated and approved by regulatory agencies in major territories only for the treatment of Erectile Dysfunction (ED) in adult men.

Q: Does the research on Rectivard include diverse patient groups?

A: Clinical trials evaluated the medicine in specific patient subgroups that are characterized by functional limitations, including men with co-existing diagnoses like Type 1 or Type 2 Diabetes Mellitus and hypertension.

Q: How long were the clinical trials for Rectivard?

A: The main pivotal studies that demonstrated effectiveness were typically Randomized Controlled Trials (RCTs) conducted for approximately 12 weeks in duration. Some post-marketing research included longer follow-up periods.

Q: Why do some people stop taking Rectivard?

A: Clinical trial data showed a discontinuation rate due to adverse events of 3.4% for the drug compared to 1.1% for placebo. The most common adverse reactions reported by patients that may lead to stopping the medicine include headache, flushing, and nasal congestion.

Storage and Disposal Requirements for Rectivard

Rectivard (Vardenafil) must be stored according to regulatory standards to maintain its quality and potency.

---

Storage Conditions

Rectivard must be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and should be stored away from excess heat and moisture.

• Container Rules: Keep the medicine in its original container, tightly closed. Orally Disintegrating Tablets (ODT) must remain in the sealed blister pack until immediately prior to use.
• Child Safety: All product must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Rectivard must be disposed of according to established guidelines. Users should consult a pharmacist or healthcare professional for instructions on proper disposal.

The medicine should not be disposed of by flushing it down the toilet or pouring it into a drain, ensuring compliance with local pharmaceutical waste regulations.